Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI

J. Delgado, M. Doubek, T. Baumann, J. Kotaskova, S. Molica, P. Mozas, A. Rivas-Delgado, F. Morabito, S. Pospisilova, E. Montserrat,

. 2017 ; 92 (4) : 375-380. [pub] 20170213

Language English Country United States

Document type Journal Article, Validation Study

Persistent link   https://www.medvik.cz/link/bmc17031098

Grant support
NV15-30015A MZ0 CEP Register
NV15-31834A MZ0 CEP Register

Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, intermediate-, and high-risk groups, respectively. Patients with low-risk comprised around 50% of the series and had a life expectancy comparable to the general population. The prognostic model was fully validated in two independent cohorts, including 417 patients representative of general CLL population and 337 patients with Binet stage A CLL. The model had a similar discriminatory value as the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, and separated patients with different risk within Rai or Binet clinical stages. The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI and could be useful in daily practice and to stratify patients in clinical trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031098
003      
CZ-PrNML
005      
20201105114526.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.24660 $2 doi
035    __
$a (PubMed)28120419
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Delgado, Julio $u Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
245    10
$a Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI / $c J. Delgado, M. Doubek, T. Baumann, J. Kotaskova, S. Molica, P. Mozas, A. Rivas-Delgado, F. Morabito, S. Pospisilova, E. Montserrat,
520    9_
$a Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, intermediate-, and high-risk groups, respectively. Patients with low-risk comprised around 50% of the series and had a life expectancy comparable to the general population. The prognostic model was fully validated in two independent cohorts, including 417 patients representative of general CLL population and 337 patients with Binet stage A CLL. The model had a similar discriminatory value as the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, and separated patients with different risk within Rai or Binet clinical stages. The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI and could be useful in daily practice and to stratify patients in clinical trials.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a kohortové studie $7 D015331
650    _2
$a geny pro těžké řetězce imunoglobulinů $7 D050438
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a chronická lymfatická leukemie $x diagnóza $x mortalita $7 D015451
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a míra přežití $7 D015996
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Brno, Czech Republic. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Baumann, Tycho $u Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
700    1_
$a Kotaskova, Jana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Brno, Czech Republic. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Molica, Stefano $u Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
700    1_
$a Mozas, Pablo $u Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
700    1_
$a Rivas-Delgado, Alfredo $u Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
700    1_
$a Morabito, Fortunato $u UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
700    1_
$a Pospisilova, Sarka $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Brno, Czech Republic. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Montserrat, Emili $u Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 92, č. 4 (2017), s. 375-380
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28120419 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20201105114523 $b ABA008
999    __
$a ok $b bmc $g 1254691 $s 992125
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 92 $c 4 $d 375-380 $e 20170213 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$a NV15-30015A $p MZ0
GRA    __
$a NV15-31834A $p MZ0
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options